Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq data of mouse B16-F10 melanoma cell lines after siEzh2 knockdown or GSK126 methyl-transferase inhibitor or DZNep treatment

ABSTRACT: Enhancer of zeste homolog 2 (EZH2) plays critical roles in the progression of many malignancies including melanoma. The most well-known EZH2 mechanism is regulating gene expression through catalysing tri-methylation of histone H3 at Lys 27 (H3K27me3). However, EZH2 also have methylation-independent activities that limit the therapeutic potential of EZH2 methyl-transferase inhibitors. To investigate the methyl-transferase independent role of EZH2 in melanoma, we performed global gene expression analysis of B16-F10 cells treated with methyl-transferase inhibitor GSK126 or siEzh2 knockdown or the EZH2 degrader DZNep.

ORGANISM(S): Mus musculus

PROVIDER: GSE189489 | GEO | 2026/07/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression analysis after co-treatment of GSK126 and pomalidomide

Project description:To determine combination effect of GSK126 and pomalidomide at the RNA levels in EZH2 Y641 mutant DLBCL, We performed gene expression profiling in WSU-DLCL2 cell line after co-treatment of GSK126 and pomalidomide

2020-09-23 | GSE147320 | GEO

Epigenetic silencing of Th1 chemokines shapes tumor immunity, immunotherapy and patient outcome [GSK126]

Project description:To define the gene profile altered by EZH2 and H3K27me3 in response to IFNg, we performed several microarrays in primary ovarian cancer cells transfected with shEZH2 or treated with GSK126. We found that 155 and 124 genes were altered by shEZH2 and GSK126 treatment, respectively, and 20 genes were increased or decreased by both shEZH2 and GSK126 treatment. Primary ovarian cancer cells were pretreated with GSK126, or transduced with a shEZH2 lentivirus, and stimulated with IFNg for 24 hours. RNA were isolated by Rneasy kit according to the manufacturer's protocol, and applied for affymetrix microarray at University of Michigan DNA Sequencing Core

2015-08-11 | E-GEOD-71869 | biostudies-arrayexpress

Transcriptomic effects of EZH2 inhibition by DZNep in VEGF-stimulated HUVECs

Project description:Purpose: To compare transcriptome profiles of VEGF-treated HUVECs with or without the EZH2 inhibitor DZNep. Methods: HUVECs were treated with VEGF(20 ng/mL) or VEGF(20 ng/mL)+DZNep (10 μM) for 48 h. Total RNA was extracted using TRIzol, and poly(A)+ RNA was used for library construction following standard Illumina protocols. Sequencing was performed on an Illumina NovaSeq 6000 (PE150). Clean reads were obtained using fastp, mapped to the Homo sapiens genome (GRCh38) with HISAT2, assembled and quantified by StringTie, and differential expression was analyzed using edgeR. GO/KEGG analyses were performed using DAVID. Results: DZNep altered VEGF-induced gene expression, reducing pro-angiogenic genes and modulating pathways related to angiogenesis and endothelial function. Conclusions: This dataset provides RNA-seq profiling of VEGF-stimulated HUVECs with or without EZH2 inhibition and supports analysis of EZH2-regulated angiogenic signaling.

2025-12-31 | GSE311954 | GEO

Epigenetic silencing of Th1 chemokines shapes tumor immunity, immunotherapy and patient outcome [GSK126]

2015-08-11 | GSE71869 | GEO

DZNep-treated glioblastoma multiforme cancer stem cells

Project description:Overexpression of the Polycomb group protein Enhancer of Zeste Homolog 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM) (1). Based on its ability to modulate transcription of key genes implicated in cell cycle control, DNA repair and cell differentiation, EZH2 is believed to play a crucial role in tissue-specific stem cell maintenance and tumor development. Here we show that targeted pharmacologic disruption of EZH2 by the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A (DZNep), or its specific down-regulation by shRNA, strongly impairs GBM cancer stem cell self-renewal in vitro and tumor-initiating capacity in vivo. Using genome-wide expression analysis of DZNep-treated GBM cancer stem cells, we found the expression of c-myc, recently reported to be essential for GBM cancer stem cells, to be strongly repressed upon EZH2 depletion. Specific shRNA-mediated down-regulation of EZH2 in combination with chromatin immunoprecipitation (ChIP) experiments revealed that c-myc is a direct target of EZH2 in GBM cancer stem cells. Taken together, our observations provide evidence that direct transcriptional regulation of c-myc by EZH2 may constitute a novel mechanism underlying GBM cancer stem cell maintenance and suggest that EZH2 may be a valuable new therapeutic target for GBM management.

2009-11-30 | GSE18150 | GEO

shRNA profiling of human DZNep-treated glioblastoma multiforme cancer stem cells

2009-12-14 | E-GEOD-18150 | biostudies-arrayexpress

Transcriptional profiling of small intestinal tissue from Apc-deficient mice, with and without DZNeP treatment

Project description:The effect of EZH2 inhibitor DZNeP on the small intestine of mice deificient in Apc was examined with RNAseq.

2023-04-30 | GSE229639 | GEO

The effect of DZNeP-exposure on activation of hepatic stellate cells analyzed by RNA-sequencing.

Project description:DZNeP is the inhibitor of Ezh2 and paly negative roles on activation of hepatic stellate cells. We used RNA sequencing to identify the effective genes of DZNeP in rat HSCs. The primary rat HSCs was isolated and purified from SD rats, and cultured in DMEM culture medium with 20% FBS for 24 hours. Then the rat HSCs was administrated with DZNeP at 1μM concentration, or with similar volume of DMSO as negative control. 48 hour later, the cells were harvested and cell lysis was subjected to RNA-sequencing. This study identified that DZNeP regulated HSC activation through upregulating the expression of many key anti-fibrotic factors including Tgfβ signaling inhibitor: Bambi; cell cycle inhibitors: p21, Gadd45s; and immunomodulatory cytokine IL10.

2020-09-30 | GSE121736 | GEO

Transcriptional and Epigenomic profile of GSK126 or dox-mediated Ezh2 inhibition in KrasG12D/+;Trp53-/-;Ezh2i-GFP-2A-rTA;Luc lung tumors in vivo

Project description:We wanted to understand the consequences of GSK126-mediated Ezh2 inhibition in an orthotopic model of Kras-driven non-small cell lung cancer (NSCLC). We injected the NSCLC cells with above-mentioned genotype into Nude mice and treated them with GSK126 50mg/kg (daily) or vehicle. As additional control for Ezh2 specificity we treated one tumor with doxycycline that induces shRNA-mediated Ezh2 protein downregulation in those cells. Purified tumour cells were obtained by dissection and FACS sorting based of GFP expression. This experiment contributes the genome-wide response of NSCLC cells to Ezh2 inhibition in vivo.

2018-04-01 | GSE61125 | GEO

Inhibition of EZH2 in THP-1 cells

Project description:Macrophages play a key role in both innate and adaptive immunity, but our knowledge on the changes in transcription regulation that occurs during their differentiation from monocytes is still limited. In this study, we used a meta-analysis followed by a systems biology approach for the identification of differentially expressed genes between monocytes and macrophages and possible regulators of these changes in transcription. Based on the pattern of gene expression change, transcription regulator analysis predicted a decrease in Enhancer of Zeste homolog 2 (EZH2), a histone 3 lysine 27 methyl transferase, activity after differentiation of monocytes into macrophages. This inhibition was validated by a significant decrease in trimethylated H3K27 during differentiation of both human primary monocytes into macrophages and the THP-1 cell line into macrophage-like cells. Overexpressing EZH2 during differentiation of monocytes and THP-1 cells obstructs cellular adhesion, thus preventing the first step in differentiation. Another facet of macrophage differentiation is the cessation of proliferation, and inhibition of EZH2 by the small molecule inhibitor GSK126 in THP-1 cells indeed impedes proliferation. This study shows an important part for epigenetic changes during monocyte differentiation. It highlights the role of EZH2 activity behind the changes needed in adhesion and proliferation mechanisms for macrophage formation. THP-1s were treated with the EZH2 inhibitor GSK126 for phenotypic and genotypic analysis.

2015-08-04 | E-GEOD-71671 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data